ArticleBMC infectious diseases2025
Epidemiology, risk factors, and antifungal susceptibility analysis of Candida tropicalis and non-C.tropicalis candidemia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genomic insights into a clade-specificmBio · 2026Article
- Non-Life (Basel, Switzerland) · 2026Article
- Epidemiology of Fungal Bloodstream Infections and Antifungal Susceptibility in a Tertiary Care Hospital in Riyadh, Saudi Arabia: A RarePathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In recent years, the incidence of Candida tropicalis bloodstream infections has been increasing annually, drawing increasing clinical attention. This study aimed to investigate the epidemiological characteristics, risk factors, and antifungal susceptibility patterns of C. tropicalis and non-C. tropicalis species among patients with candidemia at Nanjing Drum Tower Hospital from March 2020 to February 2024. A retrospective analysis was conducted on 209 patients, revealing that C. tropicalis accounted for 17.22% of cases, with a notable prevalence in medical departments, especially in hematology. Hematological diseases emerged as an independent risk factor for C. tropicalis candidemia. Antifungal susceptibility testing indicated higher resistance rates to azole drugs in C. tropicalis compared to non-C. tropicalis species, while susceptibility to echinocandin and amphotericin B was maintained. MALDI-TOF MS clustering analysis of 30 C. tropicalis isolates identified a specific subtype concentration of azole-resistant isolates, suggesting a genetic link to resistance. These findings underscore the growing significance of C. tropicalis in candidemia, highlighting the importance of understanding its clinical and resistance profiles to optimize antifungal therapy and enhance patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.